These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 18779504

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
    Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP.
    J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
    Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, Schultz L.
    J Neurooncol; 2009 Mar; 92(1):57-63. PubMed ID: 19011763
    [Abstract] [Full Text] [Related]

  • 5. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.
    J Clin Oncol; 2009 Dec 10; 27(35):5881-6. PubMed ID: 19901104
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.
    J Neurooncol; 2015 Mar 10; 122(1):111-9. PubMed ID: 25534576
    [Abstract] [Full Text] [Related]

  • 7. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M, GICNO.
    J Clin Oncol; 2006 Oct 10; 24(29):4746-53. PubMed ID: 16954518
    [Abstract] [Full Text] [Related]

  • 8. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.
    Neuro Oncol; 2012 Jan 10; 14(1):109-16. PubMed ID: 22039037
    [Abstract] [Full Text] [Related]

  • 9. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.
    J Neurooncol; 2014 Jan 10; 116(2):275-82. PubMed ID: 24162810
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.
    Neuro Oncol; 2013 Jun 10; 15(6):775-82. PubMed ID: 23486687
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
    Neurol Med Chir (Tokyo); 2007 Aug 10; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low-grade and anaplastic oligodendroglioma.
    Van Den Bent MJ, Bromberg JE, Buckner J.
    Handb Clin Neurol; 2016 Jun 20; 134():361-80. PubMed ID: 26948366
    [Abstract] [Full Text] [Related]

  • 17. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
    Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.
    Neuro Oncol; 2017 Oct 01; 19(10):1380-1390. PubMed ID: 28472509
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY.
    Clin Cancer Res; 2009 Jan 01; 15(1):330-7. PubMed ID: 19118062
    [Abstract] [Full Text] [Related]

  • 19. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
    Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society.
    Lancet Oncol; 2012 Jul 01; 13(7):707-15. PubMed ID: 22578793
    [Abstract] [Full Text] [Related]

  • 20. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.
    Chin Med J (Engl); 2010 Dec 01; 123(24):3566-73. PubMed ID: 22166632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.